Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels

Abstract

Protein abundance and phosphorylation convey important information about pathway activity and molecular pathophysiology in diseases including cancer, providing biological insight, informing drug and diagnostic development, and guiding therapeutic intervention. Analyzed tissues are usually collected without tight regulation or documentation of ischemic time. To evaluate the impact of ischemia, we collected human ovarian tumor and breast cancer xenograft tissue without vascular interruption and performed quantitative proteomics and phosphoproteomics after defined ischemic intervals. Although the global expressed proteome and most of the >25,000 quantified phosphosites were unchanged after 60 min, rapid phosphorylation changes were observed in up to 24% of the phosphoproteome, representing activation of critical cancer pathways related to stress response, transcriptional regulation, and cell death. Both pan-tumor and tissuespecific changes were observed. The demonstrated impact of pre-analytical tissue ischemia on tumor biology mandates caution in interpreting stress-pathway activation in such samples and motivates reexamination of collection protocols for phosphoprotein analysis. Molecular

Nuclear Matrix Protein 4 Is a Novel Regulator of Ribosome Biogenesis and Controls the Unfolded Protein Response via Repression of Gadd34 Expression

“…3B). This suggests that protein modifications identified in NMP4 (39,40) or availability of NMP4 interacting proteins (36) may play a role in regulating the localization and activity of NMP4 in response to cellular cues to modulate protein production and secretion (21).…”

Mitotic protein kinase CDK1 phosphorylation of mRNA translation regulator 4E-BP1 Ser83 may contribute to cell transformation

“…HeLa cells were disrupted, and proteins were tryptically digested, phosphopeptide enriched, TMT10 labeled, and high mass accuracy LC-MS/MS analyzed as previously described (47). Variations include use of TMT10 instead of iTRAQ labeling, cell lysate vs. tissue disruption, and use of Q Exactive Orbitrap MS. HEK293 cell LC-MS/MS analyses were performed identically, except for quantitation that used label-free approaches as previously described (48).…”

QuantFusion: Novel Unified Methodology for Enhanced Coverage and Precision in Quantifying Global Proteomic Changes in Whole Tissues

“…Tumor Sample Generation and Protein Extraction-Patient-derived xenograft (PDX) breast tumors were established (27,28) and processed to cryopulverized powders (4,14). The powders (100 mg wet weight) were subjected to lysis and protein extraction using a buffer composed of 8 M urea, 50 mM Tris, pH 8.0, 75 mM NaCl, 1 mM MgCl 2 , and 500 units Benzonase.…”

“…However, the integration of accuracy, sensitivity, and totality in the analysis of tumor-specific proteoforms from individual patients still remains challenging with the current quantitative platforms. For example, strategies to increase analytical throughput (12) for tumor analysis have utilized the multiplexing advantage of isobaric mass tags such as tandem mass tags or isotope tagging for relative and absolute quantitation (13,14). However, for routine quantitative analysis of large scale peptides/proteins, tandem mass tags and isotope tagging for relative and absolute quantitation reagents are prohibitively expensive due to the requirement of large amounts of protein as input.…”